Download PDF


Nils Wilking and Bengt Jonsson's follow on from their studies in 2005 and 2007 has shown the same result: access to modern cancer treatments differs greatly from country to country. The report has shown that the broadest access to new treatments are found in Austria, France and Switzerland while Poland, the Czech Republic and Britain are trailing behind.

The study was financed by an unrestricted grant from European drugmakers who have long protested these inequalities and restrictions in accessing expensive new cancer drugs.

«« Roche Launches New Knowledge and Competence Support Platform


Hospital Mobile Phone Ban to be Lifted »»


Latest Articles

  • Pharmacist in the ICU

    Pharmacists play a crucial role in the ICU, where patients often require complex medication regimens, including multiple medications and intravenous therapies. The role of a critical care pharmacist is multifaceted and vital to ensuring optimal patient care in the critical care setting.   Cr

    READ MORE
  • Defining Medicines Optimisation in the Intensive Care Unit

      Complex polypharmacy and pathophysiology are common in the intensive care unit (ICU). Medicines optimisation is essential to deliver safe, effective, and individualised pharmacotherapy. This is ideally performed by a specialised ICU pharmacist.   Introduction Medicines ar

    READ MORE
  • Critical Care Pharmacists Save Lives

      The purpose of this review is to discuss the role of critical care pharmacists on the interprofessional healthcare team in the care of critically ill patients and explore current gaps in the provision of comprehensive medication management.   Introduction   “The patient’s

    READ MORE
Nils Wilking and Bengt Jonsson's follow on from their studies in 2005 and 2007 has shown the same result: access to modern cancer treatments differs grea...